 |
| Mark your calendars! |
Whether you have been following the Fujifilm v AbbVie case every step of the way or you are coming to it afresh, do not fear! Next week's Rapid Response event organized by AIPPI UK will be everything you need to understand how this decision will effect you, your clients and future litigation strategies. Here come the details:
Date: Thursday, 6 April 2017
Time: 5:30PM for 6PM
Place: Allen & Overy, Bishops Square, London E1 6AD
Who: Michael Silverleaf QC, Mike Brealey QC, Ravi Srinivasan
What: Mr Justice Henry Carr’s judgment of 3 March 2017 was the first time that relief has been ordered by the English Courts in the form of an Arrow declaration. In this special event, a panel of distinguished speakers will review the decision from the perspective of patent law, competition law and patent prosecution strategy to assess whether the circumstances of the case were sufficiently unusual to make this a one-off decision or whether this marks the beginning of a new trend in biosimilars patent litigation where patent thickets are dense and the need for commercial certainty high. AbbVie was alleged to be avoiding adjudication on the validity of its patents. Was the declaration justified or was AbbVie merely operating within the rules?
The AmeriKat encourages speedy registration as this is promising to be a blockbuster event, including some helpful suggestions on how best to benefit from this revamped litigation tool. For those who can't attend, there will be an IPKat report on the evening's proceedings soon after. In the meantime, you can get yourself up to date with these handy Kat summary
here and
here.
